

In're of Appln. No. 09/687,122
Amdt. dated Apr. 2, 2004
Reply to Office action of Dec. 2, 2003

Amendments to the Claims:

This listing of the claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-20 (Cancelled)

21 (Currently Amended). ~~A~~ In a method for treating autoimmune and inflammatory diseases against which a tumor necrosis factor (TNF) receptor is effective in a patient which comprises by administering to the patient an effective amount of a tumour necrosis factor (TNF) receptor, the improvement wherein said TNF receptor is administered in combination with dehydroepiandrosterone (DHEA) simultaneously, separately or sequentially, thereby treating the autoimmune or inflammatory disease.

22 (Withdrawn). The method of claim 21, wherein the TNF receptor is TNF Binding Protein-2.

23 (Withdrawn). The method of claim 22, wherein the disease treated is autoimmune disease.

24 (Withdrawn). The method of claim 22, wherein the disease treated is inflammatory disease.

25 (Previously Presented). The method of claim 21, wherein the TNF receptor is TNF Binding Protein-1.

26 (Previously Presented). The method of claim 25, wherein the disease treated is autoimmune disease.

In're of Appln. No. 09/687,122
Amdt. dated Apr. 2, 2004
Reply to Office action of Dec. 2, 2003

27 (Previously Presented). The method of claim 25, wherein the disease treated is inflammatory disease.

28 (Previously Presented). The method of claim 21, wherein the disease treated is autoimmune disease.

29 (Previously Presented). The method of claim 21, wherein the disease treated is inflammatory disease.

30 (Currently Amended). The method of claim 21, wherein said autoimmune or inflammatory disease is ~~septic~~ shock rheumatoid arthritis, lupus erythematosus, or multiple sclerosis.

31 (Previously Presented). The method of claim 30, wherein the TNF receptor is TNF binding protein-1.

32 (Withdrawn). The method of claim 30, wherein the TNF receptor is TNF Binding Protein-2.